Table S1 Studies summaries of FTY720 in various cancer mouse models

	First author, year,country	
Animal strain and age （n=experiment group/ control group)
	Dosage, frequency and duration	Location	Administration	Drug control	Cell lines/number
	Cancer types
	
1	Yang Li
2018, China	BALB/c nude mice (n=5/5),
6 weeks	5 mg/kg/day, 18 days	sc	po	PBS	
human cell lines A549/DDP,
1x107	non-small lung cancer	
2	Manendra Babu Lankadasari
2018, India	NOD. CB17-Prkdcscid/J mice (n=5/5), 7-8 weeks	1 mg/kg/day, 28 days	orthotopic	po	saline
	MIAPaCa2-luc cells,
1×106	pancreatic cancer	
3	Kelly M. Kreitzburg
2018, USA	female CB17−/−SCID mice (n=8/6), NA	5 mg/kg/day, 25 days	sc	ip	vehicle	patient PDX127R ovarian carcinoma cells, NA	ovarian cancer	
4	Agata Szymiczek
2017, USA	Balb/c mice (n=15/15),
8 weeks	10mg/kg, in a 5-day-on, 2-day-off schedule, 16 days	sc	ip	2% DMSO solution in water	mouse AB1 cells,
1×105	mesothelioma	
5	Yuki Muroyama
2017, USA	female wild-type C57BL/6 mice (n=7/7), 4-8 weeks	25 μg every 3 days, on day 6,9,10	sc	po	PBS	mouse B16/F10 cells,
5×105	melanoma	

6	Janet L. Martin
2017, Australia	female BALB/c nude/wild type mice, 6-7 weeks (n=5/5; 10/10; 10/10；10/10)
nude/nude/nude/wt	3 mg/kg or 5 mg/kg, three times weekly, duration from 6 days to 25 days	orthotopic	ip	vehicle	MDA-MB-468 cell , HCC1806 cell, 4T1 murine mammary carcinoma cells,
5×106; 5×106; 1×105; 1×105	triple negative breast cancer	
7	Veronica Lifshitz
2017, USA	male NOD/SCID/interleukin 2 gamma-receptor-null (NSG) mice (n=6/4; 5/5), 8 weeks	5 mg/kg/day, 5 days a week for a total of 2 weeks	sc	ip	vehicle	human CHLA-255/Fluc cells, CHLA-255 etoposide-resistant cell,
5×106, 5×106	neuroblastoma	
8	Eriko Katsuta
2017, USA	female C57BL/6 mice (n=6/6), NA	1 mg/kg/day, 12 days	orthotopic	po	NA	E0771 cells,
1×106	breast cancer	
9	Heba Alshaker
2017, UK	female BALB/c nude mice (n=6/6), 6-8 weeks	3 mg/kg, for 2 weeks,  biweekly	orthotopic	iv	1% DMSO saline	murine 4T1 cells,
1×106	triple negative breast cancer	
10	Masayuki Nagahashi
2016, US	female Balb/c mice (n=5/5), 8-10 weeks	1 mg/kg/day, 14 days	orthotopic	po	saline	murine 4T1-luc2 cells,
1×105	breast cancer	
11	Cecil Gstealder
2016, France	female NMRI/Nu (nu/nu)mice (n=6/6), 
6 weeks	2.5 mg/kg/day, 
14 days	sc	NA	DMSO	human CAKI-1 cells,
1×106	renal cell carcinoma	
12	Wohn-Jenn Leu
2016, China, Taiwan	nude mice (n=6/6), NA	5 mg/kg/day, 13 days	sc	ip	vehicle 	human PC-3 cells,
1×107	prostate cancer	
13	NC Hait
2015, USA	Female PyMT transgenic mice (n=5/5); BALB/c mice(n=8/8), 6weeks; 8-12weeks	1 mg/kg/day, 
4 weeks; 1mg/kg/day, 13 days	orthotopic	po	vehicle	ERα-negative 4T1 cells ,
NA	breast cancer	

14	Seon Min Woo
2015, South Korea	male BALB/c-nude mice (n=7/7), 5 weeks	7.5 mg/kg, three times a week for 
4 weeks	sc	ip	vehicle	human Caki cells,
2×106
	renal cell carcinoma	
15	Hao Liu
2015, China	immunodeficient mice (SCID) (n=9/9), 4-6 weeks
	3 mg/ kg/day, 
18 days	sc	ip	DMSO	human A549,
1×106	non-small cell lung cancer	
16	Yunze Xu
2015, China	female athymic mice(n=5/5), 4-6 weeks	10 mg/kg/day, 
10 days	sc	ip	saline	H295R cells,
2×106	adrenocortical carcinoma	
17	Hao Liu
2014, China	immunodeficient mice (n=9/9), 4-6 weeks	1 mg/kg/day, 18 days	sc	ip	vehicle	human A549/CDDP,
5×105	non-small cell lung cancer	
18	Limin Chen
2014, China	female nude mice (nu/nu) (n=7 or 8 mice per group), 5-6 weeks	1 mg/kg/day or 5 mg/kg/day for 3 weeks	sc	ip	5% glucose	human Kasumi-1 cells,
3×107	acute myelogenous leukemia	
19	Roberta Rosa
2013, Italy
	Balb/c athymic (nu/nu) mice (n=10/10), 5 weeks	2.5 mg/kg, 3 times a week for 3 weeks	sc	ip	NA	human GEO-CR cells,
1×107	colorectal cancer	
20	Mei-Hong Li
2013, USA	male athymic NCr-rnu/nu nude mice (n=5/5), 6 weeks	5 mg/kg/day, 
14 days	sc	ip	vehicle	human SK-N-AS cells,
1×107	neuroblastoma	
21	Adriana Estrada-Bernal
2012, USA	female athymic mice nude/nude genotype (n=3/3),  5-6 weeks	10 mg/kg/day, 
11 days	orthotopic	ip	vehicle	patient BTSC9 cells,
2×105	glioblastoma	
22	Dmitri Pchejetski
2010, France	male NMRI/Nu (nu/nu)mice (n=8/8), 7 weeks	2.5 mg/kg/day,
2 weeks	sc	ip.	PBS	human PC-3 cells
1×106	prostate cancer	
23	Gerald Schmid
2007, Germany	C57BL/6 mice (n=9/9), NA	10 mg/kg/day, 
14 days	sc	ip	PBS	murine LLC1
8×105	lung cancer	
24	Terence K. Lee
2005, China	nude mice (n=12/12; 12/12), NA	5 or 10 mg/kg/day, 35 days	orthotopic	ip	control	human cell lines MHCC-97L and MHCC-97H
NA	hepatocellular carcinoma	
25	Joanna W.Y. Ho
2005, China	male athymic nude mice (BALB/c-nu/nu)（n=15/15; 15/15）, 4-6 weeks	10 mg/kg/day, 
20 days	NA	ip	vehicle	PLC/PRF/5 cells；Huh7 cells
NA	hepatocellular carcinoma	
26	Chee-Wai Chua
2005, China	male athymic nude castrated mice (n=11/11), 4-5 weeks	10 mg/kg/day, 
20 days	sc	ip	normal saline	human CWR22R cells
NA	androgen-inde-pendent prostate cancer	
27	Haruhito Azuma
2002, Japan	BALB/c-nu/nu mice (n=30/30/30/90), NA	2 /5/10 mg/kg/day, 24 days	sc	ip	NA	JygMC(A) cells
1×107	breast cancer	
28	Terence K.Lee
2004, China	male BALB/c nu/nu mice (n=8/7), 4 weeks	10 mg/kg/day, 
20 days	sc	ip	NA	Hep3B strain cells
NA	hepatocellular carcinoma	
29	Ela Markovsky
2019, USA	BALB/c mice (n=3/3),
12 weeks	NA	orthotopic	ip	NA	67R cells
NA	breast cancer	
30	Y Li
2017, China	syngeneic Balb/c or C57BL/6 background (n=8-10 per group), Balb/c mice (n=5-6 per group) and SCID micemice (n=5/5), NA	1 mg/kg/day for 3 weeks; 
0.3 mg/kg/day for 21 days;
 1mg/kg/day for 21 days	sc	po	NA	CT26 murine colon carcinoma cells;  LLC murine lung adenocarcinoma cells and B16 murine melanoma cells 
NA	colon carcinoma ,
lung adeno carcinoma,
melanoma

31	Yoanne Mousseau
2012, France	female Sprague –Dawley rats (n = 10/10), 8 weeks	5 mg/kg/day, 11 days	orthotopic	po	NA	Walker 256 cell
1×104	breast cancer	

wt, wild type; ip, intraperitoneal injection; iv, vein injection; sc, subcutaneous; DMSO, dimethyl sulfoxide; NA, not available